CGT Sanofi has “no illusions about the cardboard promises that will be made by ministers”

“What we demand is that Opella remains in Sanofi and that Sanofi is a little more constrained today by the authorities,” says Fabien Mallet, CGT coordinator of the pharmaceutical group.

Published


Reading time: 2 mins

On the Doliprane production site in Lisieux. (MYCHELE DANIAU / AFP)

“We are surprised to see two ministers come to provide after-sales service for Sanofi,” scathed the CGT coordinator of the pharmaceutical group Fabien Mallet on Monday October 14 on franceinfo, while the Minister of the Economy Antoine Armand and his Industry counterpart Marc Ferracci are in Lisieux (Calvados), on the Doliprane production site.

Sanofi announced at the end of last week that it had chosen the American investment fund CD&R to cede control of its subsidiary Opella, responsible in particular for the manufacture of Doliprane, the best-selling drug in France. The opportunity for Fabien Mallet to denounce “a cut-out sale” of a “tool which has the capacity to provide treatment at the French and European level”.

“We have no illusions about the cardboard promises that will be made to ministers today,” launched the union delegate, deploring “once again” the existence of a “quite important and quite incestuous link between macronie and the management of Sanofi”. “We still have two ministers who travel to reassure Sanofi employees about their future”Fabien Mallet was surprised.

If the Minister of Industry said on Sunday that he was wondering about the possibility of blocking the sale via the foreign investment control procedure, “The question we ask ourselves is why this hasn’t already been done?” asked the trade unionist. “We have to do it now,” he pushed, calling for “politicians take their responsibilities”.

“Sanofi is several billions of public money paid to it through various means, with the return being a dismantling of one of the largest European pharmaceutical multinationals.”

Fabien Mallet, CGT coordinator

at franceinfo

“What we are asking and what we are demanding is that Opella remains in Sanofi and that Sanofi is a little more constrained today by the authorities, whether European or French,” indicated the CGT union delegate, specifying that the nationality of the investment fund was not in question. “All investment funds, whether French, American, German, Qatari, have the same methodology: to make money”he shouted.


source site-14

Latest